The Drug That Ended 30 Years of "Undruggable": Rasonque Posts $197.6 Million in Its First Five Weeks
· techtimes.com · popularity 16/100 · 0 similar stories today · Cancer & Oncology (Health & Life Sciences)
Read the original at techtimes.com →
Summary
Revolution Medicines' Rasonque (daraxonrasib) posted $197.6M in its first five weeks after FDA approval -- doubling survival in a Phase 3 pancreatic cancer trial.
Found in: Tech Times. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 18.